|
2015 Conference Publication Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)Scherer, Florian, Kurtz, David Matthew, Green, Michael Richard, Newman, Aaron M., Klass, Daniel M., Zhou, Li, Krishnan, Rashi, Liu, Chih Long, Glover, Cynthia, Ohgami, Robert S., Hicks, Rodney J., Keane, Colm, Kong, Katherine A., Faham, Malek, Hertzberg, Mark S., Gandhi, Maher K., Advani, Ranjana H., Levy, Ronald, Diehn, Maximilian and Alizadeh, Ash A. (2015). Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL). Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, United States, May 29-June 2, 2015. Alexandria, United States: American Society of Clinical Oncology. |
|
2015 Conference Publication Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratiosLecao K.-A., Keane C., Han E., Talaulikar D. and Gandhi M. (2015). Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios. Scientific Stream at Big Data in Health Analytics 2015, BigData 2015, Sydney; Australia, October 20, 2015-October 21, 2015. Aachen, Germany: Rheinisch-Westfaelische Technische Hochschule Aachen. |
|
2014 Conference Publication Validation of Elevated Blood Soluble PD-L1 As an Independent Prognostic Marker in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Fest, Thierry, Cerhan, James R., Gandhi, Maher K., Azzaoui, Imane, Crooks, Pauline, Maurer, Matthew J., Milpied, Noel, Hertzberg, Mark S., Lamy, Thierry, Ansell, Stephen M., Slager, Susan L., Feldman, Andrew L., Roussel, Mikael, Habermann, Thomas M., Ghesquieres, Herve, Witzig, Thomas E., Link, Brian K. and Rossille, Delphine (2014). Validation of Elevated Blood Soluble PD-L1 As an Independent Prognostic Marker in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). 56th Annual Meeting of the American Society of Hematology, San Francisco, CA United States, 06-09 December 2014. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.V124.21.2998.2998 |
|
2014 Conference Publication Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCLKurtz, David Matthew, Green, Michael R., Bratman, Scott Victor, Liu, Chih-Long, Glover, Cynthia, Keane, Colm, Kong, Katie, Faham, Malek, Miklos, David Bernard, Advani, Ranjana H., Levy, Ronald, Hertzberg, Mark S., Gandhi, Maher K., Diehn, Maximilian and Alizadeh, Ash A. (2014). Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. 50th Annual Meeting of the American Society of Clinical Oncology, Chicago IL United States, May 30-June 3, 2014. Alexandria VA, United States: American Society of Clinical Oncology. |
|
2013 Conference Publication HLA-Class I Alleles Impact Susceptibility To EBV+ Classical Hodgkin Lymphoma By Altering EBV Latent Antigen-Specific CD8(+) T-Cell Immune HierarchiesGandhi, Maher K., Brennan, Rebekah M., Wockner, Leesa, Chattopadhyay, Pratip K., Roederer, Mario, Price, David A., Cole, David K., Hassan, Brekhna, Beck, Konrad, Thornton, Alycia, Gottlieb, David, Ritchie, David, Seymour, John F., Kumarasinghe, Gayathri, Burrows, Scott R. and Jones, Kimberley (2013). HLA-Class I Alleles Impact Susceptibility To EBV+ Classical Hodgkin Lymphoma By Altering EBV Latent Antigen-Specific CD8(+) T-Cell Immune Hierarchies. 55th Annual Meeting of the American-Society-of-Hematology, New Orleans La, Dec 07-10, 2013. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2013 Conference Publication FOXP1 truncated isoforms differentially regulate target genes in diffuse large B cell lymphoma.Camilleri, Emily, Aya-Bonilla, Carlos, Nourse, Jamie, Brown, Philip J., Banham, Alison H., Marlton, Paula, Gandhi, Maher K. and Griffiths, Lyn R. (2013). FOXP1 truncated isoforms differentially regulate target genes in diffuse large B cell lymphoma.. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. doi: 10.1158/1538-7445.TUMIMM2012-B38 |
|
2013 Conference Publication Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant PatientsTaylor, Emma, Jones, Mark, Hourigan, Matthew J., Johnson, David W., Gill, Devinder S., Isbel, Nicole, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher K., Campbell, Scott B. and Mollee, Peter (2013). Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant Patients. 55th Annual Meeting of the American Society of Hematology, New Orleans, LA United States, 7-10 December 2013. Washington, DC United States: American Society of Hematology. |
|
2012 Conference Publication Lymphocyte Counts in Patients with B-Cell Non-Hodgkin Lymphoma and Correlation with Fc Gamma Receptor PolymorphismsTalaulikar, Dipti, Cendales, Yvonne Gonzalez, Shadbolt, Bruce, Gandhi, Maher and Warren, Hilary (2012). Lymphocyte Counts in Patients with B-Cell Non-Hodgkin Lymphoma and Correlation with Fc Gamma Receptor Polymorphisms. MALDEN: WILEY-BLACKWELL. |
|
2012 Conference Publication Modulation of the unfolded protein response via XBP1 splicing: a novel mechanism that regulates Natural Killer cell effector function.Mujaj, Sally, Gandhi, Maher, Vari, Frank and Nourse, Jamie (2012). Modulation of the unfolded protein response via XBP1 splicing: a novel mechanism that regulates Natural Killer cell effector function.. 99th Annual Meeting of the American-Association-of-Immunologists, Boston Ma, May 04-08, 2012. BETHESDA: AMER ASSOC IMMUNOLOGISTS. |
|
2012 Conference Publication Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin LymphomaGandhi, Maher K., Vari, Frank, Crooks, Pauline, Keane, Colm, Nourse, Jamie P., Seymour, Louise A., Ritchie, David, Gottlieb, David, Gill, Devinder and Jones, Kimberley (2012). Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma. 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta GA, United States, 8-11 December 2012. Washington, DC United States: American Society of Hematology. |
|
2012 Conference Publication Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell LymphomaCamilleri, Emily T., Aya-Bonilla, Carlos A., Brown, Philip J., Banham, Alison, Marlton, Paula, Gandhi, Maher K. and Griffiths, Lyn R. (2012). Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell Lymphoma. 54th Annual Meeting and Exposition of the American Society of Hematology (ASH), Atlanta, GA, United States, 8-11 December 2012. Washington, DC, United States: American Society of Hematology. |
|
2011 Conference Publication A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A PolymorphismsHuyen Tran, , Nourse, Jamie P., Lea, Rod, Brighton, Timothy A., Grigg, Andrew, McRae, Simon, Thurley, Daniel, Gandhi, Maher and Catalano, John (2011). A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2011 Conference Publication Tissue microarray in DLBCL patients receiving R-CHOP chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6Keane, Colm, Shen, Linda, Han, Erica, Nourse, Jamie P, Lea, Rod, Mollee, Peter, Gill, Devinder S and Gandhi, Maher K (2011). Tissue microarray in DLBCL patients receiving R-CHOP chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6. 53rd ASH Annual Meeting, San Diego, 10-13 December 2011. American Society of Hematology. doi: 10.1182/blood.v118.21.1585.1585 |
|
2011 Conference Publication Tissue microarray in DLBCL patients receiving CHOP-R chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6 and poor outcome for EBER-ISH positive patientsKeane, C., Shen, L., Nourse, J., Han, E., Jones, K. and Gandhi, M. (2011). Tissue microarray in DLBCL patients receiving CHOP-R chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6 and poor outcome for EBER-ISH positive patients. 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, 15-18 June 2011. Oxford, United Kingdom: Oxford University Press. |
|
2011 Conference Publication Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6Keane, C, Shen, L, Han, E, Nourse, JP, Lea, R, Mollee, P, Gill, DS and Gandhi, MK (2011). Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2011 Conference Publication Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCLGandhi, MK, Hertzberg, MS, Han, E, Seymour, JF, Hicks, R, Gill, DS, Keane, C, Crooks, P, Radford, K and Vari, F (2011). Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2010 Conference Publication Ebv-Positive Dlbcl of the Elderly Is a Distinct Clinico-Biological Entity with Poor Outcome in Chop-R Treated PatientsGandhi, M., Keane, C., Nourse, J., Jones, K., Ross, N., Han, E. and Nguyen-Van, D. (2010). Ebv-Positive Dlbcl of the Elderly Is a Distinct Clinico-Biological Entity with Poor Outcome in Chop-R Treated Patients. 15th Annual Meeting of the European-Hematology-Association, Barcelona Spain, June 10-13, 2010. Pavia, Italy: Fondazione Ferrata Storti. |
|
2009 Conference Publication EBV MicroRNA Expression in Virus Driven B-Cell Differentiation and LymphomagenesisNourse, Jamie P., Crooks, Pauline, Van, Do Nguyen, Jones, Kimberley, Ross, Nathan and Gandhi, Maher K. (2009). EBV MicroRNA Expression in Virus Driven B-Cell Differentiation and Lymphomagenesis. 51st Annual Meeting of the American-Society-of-Hematology, New Orleans La, Dec 05-08, 2009. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2009 Conference Publication Cell-free Epstein-Barr Virus DNA is a Specific Biomarker for Tumor Burden in EBV-associated LymphomasJones, Kimberley, Nourse, J., Crooks, P., Gottlieb, D. and Gandhi, Mahei (2009). Cell-free Epstein-Barr Virus DNA is a Specific Biomarker for Tumor Burden in EBV-associated Lymphomas. 24th Annual Meeting of the International-Society-for-Biology-Therapy-of-Cancer, Washington Dc, Oct 29-31, 2009. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2009 Conference Publication Mechanisms Underlying the Selective Impairment of Epstein Barr Virus-Nuclear Antigen I-specific Effector T Cells Observed in PTLDJones, Kimberley, Nouise, J., Morrison, L., Vari, Frank, Moss, D. and Gandhi, Mahei K. (2009). Mechanisms Underlying the Selective Impairment of Epstein Barr Virus-Nuclear Antigen I-specific Effector T Cells Observed in PTLD. 24th Annual Meeting of the International-Society-for-Biology-Therapy-of-Cancer, Washington Dc, Oct 29-31, 2009. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
